# Efficacy of Mefloquine as Prophylaxis Against COVID-19: A Placebo-control, Randomized Clinical Trial

> **NCT04847661** · PHASE2,PHASE3 · COMPLETED · sponsor: **Helwan University** · enrollment: 137 (actual)

## Conditions studied

- Covid19

## Interventions

- **DRUG:** Mefloquine as a prophylaxis against SARS-Cov-2 infection in household contacts of COVID 19 confirmed cases

## Key facts

- **NCT ID:** NCT04847661
- **Lead sponsor:** Helwan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-28
- **Primary completion:** 2022-06-30
- **Final completion:** 2022-06-30
- **Target enrollment:** 137 (ACTUAL)
- **Last updated:** 2023-03-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04847661

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04847661, "Efficacy of Mefloquine as Prophylaxis Against COVID-19: A Placebo-control, Randomized Clinical Trial". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04847661. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*